OTSUKA

This website is intended for healthcare professionals only.Welcome to the JINARC® (tolvaptan) training website for health care professionals in Ireland.Jinarc® is indicated to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adults with CKD stage 1 to 4 at initiation of treatment with evidence of rapidly progressing disease.Otsuka has been working with the Irish regulatory authority, the Health Products Regulatory Authority (HPRA), to provide HCPs and patients with an educational programme on the safe use of JINARC®.This program is aimed at ensuring awareness about the potential risk of hepatotoxicity associated with the use of JINARC® and guidance on how to manage this risk, as well as the importance of pregnancy prevention prior to the initiation and during the treatment with JINARC®. This program includes printed copies of educational materials for HCPs and patients, as well as digital versions available on..

Registration numbers: 3456326 (W)